Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.47 |
| ▸ | PIM1 | P11309 | 5/20 | 0.47 |
| ▸ | IGF1R | P08069 | 3/20 | 0.47 |
| ▸ | CLK2 | P49760 | 3/20 | 0.47 |
| ▸ | GSK3A | P49840 | 3/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | PRKX | P51817 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.47 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29810919 | 1.00 | PARP1 (0.47) | PARP1PIM1IGF1RCLK2GSK3A | |
| SCHEMBL21415486 | 0.81 | PARP1 (0.51) | PARP1PIM1IGF1RCLK2GSK3A | |
| SCHEMBL31559173 | 0.79 | PARP1 (0.47) | PARP1PIM1IGF1RCLK2GSK3A | |
| SCHEMBL31559483 | 0.76 | IP6K1 (0.56) | PARP1PIM1IGF1RCLK2GSK3A | |
| SCHEMBL22028973 | 0.75 | PARP1 (0.36) | PARP1PIM1PIM3PIM2CSNK2A2 | |
| SCHEMBL30826848 | 0.75 | PARP1 (0.36) | PARP1PIM1PIM3PIM2CSNK2A2 | |
| SCHEMBL23415332 | 0.74 | PARP1 (0.50) | PARP1PIM1IGF1RCLK2GSK3A | |
| SCHEMBL29888396 | 0.74 | PARP1 (0.50) | PARP1PIM1IGF1RCLK2GSK3A | |
| SCHEMBL26967419 | 0.73 | CHEK1 (0.39) | PARP1PIM1IGF1RCLK2GSK3A | |
| SCHEMBL22555248 | 0.72 | PARP1 (0.47) | PARP1PIM1IGF1RCLK2GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-RE50490-E1 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240246954-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KRAS | THERAS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
| EP-4352053-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | Eli Lilly and Company (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024063576-A1 | NOVEL QUINAZOLINE COMPOUND AS KRAS INHIBITOR | 일동제약(주) | 2024-03-28 | — | — | WO | disclosed |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-02-08 | — | — | US | disclosed |
| WO-2016164675-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016164675-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| EP-3055290-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2016049568-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246954-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KRAS | KRAS, NRAS, HRAS | PARP1 1997/4885PIM1 3096/4885IGF1R 3133/4885 |
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | KRAS, RSU1, NRAS | PARP1 3844/4885PIM1 3361/4885IGF1R 2051/4885 |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | PARP1 1612/4885PIM1 2850/4885IGF1R 1971/4885 |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | PARP1 1711/4885PIM1 3018/4885IGF1R 1186/4885 |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | KRAS, NRAS, TP53 | PARP1 1019/4885PIM1 2034/4885IGF1R 603/4885 |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | PARP1 1495/4885PIM1 3041/4885IGF1R 1852/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | PARP1 1960/4885PIM1 2998/4885IGF1R 1503/4885 |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | PARP1 1960/4885PIM1 2998/4885IGF1R 1503/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | PARP1 1418/4885PIM1 1697/4885IGF1R 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.